Short answer
Biomarin Pharmaceutical Inc (BMRN) filed an 8-K current report with the SEC on March 16, 2026 reporting Item 8.01 (Other Events). VOXZOGO Phase 2 trials halted for Turner Syndrome, SHOX-deficiency, and ACAN-deficiency after SCFE bone adverse events in two investigator-sponsored trials.
Biomarin Pharmaceutical Inc 8-K event analysis
AI summary of each reported item and its exhibits
Item 8.01 · Other Events
- VOXZOGO Phase 2 trials halted for Turner Syndrome, SHOX-deficiency, and ACAN-deficiency after SCFE bone adverse events in two investigator-sponsored trials
- Safety signal confined to investigator-sponsored studies only: no SCFE cases in BioMarin's own Phase 2 trials or in 5,000+ achondroplasia patients across 10,000+ patient-years
- Pipeline narrowing: three indications discontinued, but Noonan syndrome and ~95% of ISS enrollment continue under CANOPY trials
- Achondroplasia remains VOXZOGO's approved commercial base: no safety concern flagged there, limiting direct revenue impact
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Biomarin Pharmaceutical Inc 8-K filings
Get the next BMRN 8-K as it lands
Follow BMRN for push alerts, or ask the research agent what this filing means.